Equities Analysts Issue Forecasts for MIST FY2028 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Equities researchers at HC Wainwright lowered their FY2028 earnings per share estimates for shares of Milestone Pharmaceuticals in a research report issued on Friday, March 20th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.45 per share for the year, down from their prior estimate of $0.53. HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2029 earnings at $0.92 EPS and FY2030 earnings at $1.70 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Friday, March 20th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The firm had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $37.52 million.

Other research analysts also recently issued research reports about the stock. Zacks Research downgraded shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Wells Fargo & Company raised their price target on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Finally, Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Milestone Pharmaceuticals Stock Performance

Shares of NASDAQ MIST opened at $1.36 on Monday. The stock has a market cap of $115.83 million, a PE ratio of -1.72 and a beta of 0.48. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $3.06. The firm has a fifty day moving average price of $1.80 and a 200-day moving average price of $1.99. The company has a debt-to-equity ratio of 2.74, a current ratio of 8.24 and a quick ratio of 8.24.

Insiders Place Their Bets

In related news, CEO Joseph Oliveto sold 43,000 shares of the firm’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $2.25, for a total transaction of $96,750.00. Following the completion of the transaction, the chief executive officer directly owned 303,721 shares of the company’s stock, valued at approximately $683,372.25. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 113,693 shares of company stock worth $233,347 over the last three months. Company insiders own 19.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MIST. Creative Planning grew its position in shares of Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after purchasing an additional 10,000 shares in the last quarter. Raymond James Financial Inc. lifted its position in shares of Milestone Pharmaceuticals by 30.1% in the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after buying an additional 10,000 shares in the last quarter. Bay Rivers Group lifted its position in shares of Milestone Pharmaceuticals by 72.9% in the fourth quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after buying an additional 12,170 shares in the last quarter. Sapient Capital LLC bought a new position in Milestone Pharmaceuticals during the third quarter valued at approximately $25,000. Finally, Strategic Family Wealth Counselors L.L.C. bought a new position in Milestone Pharmaceuticals during the fourth quarter valued at approximately $25,000. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.